Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00196898 |
Recruitment Status
: Unknown
Verified April 2011 by German Parkinson Study Group (GPS).
Recruitment status was: Recruiting
First Posted
: September 20, 2005
Last Update Posted
: March 19, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Heart Valve Diseases Parkinson's Disease |

Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A National, Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson´s Disease Treated With Dopamine Agonists |
Study Start Date : | March 2005 |
Estimated Study Completion Date : | December 2013 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age > 18 years
- Diagnosis of Morbus Parkinson
- Written informed consent
Exclusion Criteria:
- Patients with a history of carcinoid syndrome
- Patients with a history of post-inflammatory (rheumatic), degenerative (calcified) or ischaemic coronary heart or valvular heart disease
- Previous medication with ergot-derived drugs (eg. Methysergide, Ergotamine) except dopamine receptor agonists or anorectic drugs (eg. Fenfluramine, Dexfenfluramine)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00196898
Contact: Karla Eggert, Dr. | +49 (0)6421 2865443 | eggert@med.uni-marburg.de | |
Contact: Wolfgang M. Oertel, Prof. Dr. | +49 (0) 6421 866278 | oertelw@med.uni-marburg.de |
Germany | |
Universitätsklinikum Marburg und Gießen, Neurologische Klinik | Recruiting |
Marburg, Hessen, Germany, 35033 | |
Contact: Wolfgang H. Oertel, Prof. Dr. + 49 6421- 28 66278 oertelw@med.uni-marburg.de | |
Contact: Karla M. Eggert, Dr. + 49 6421- 28 65443 eggert@med.uni-marburg | |
Principal Investigator: Wolfgang H. Oertel, Prof. Dr. | |
Principal Investigator: Karla M Eggert, Dr. |
Study Chair: | Wolfgang Oertel, Prof. Dr. | Universitätsklinikum Marburg und Gießen |
Additional Information:
Responsible Party: | Competence Network on Parkinson´s disease, Dr. Karla Eggert, Competence Network on Parkinson´s disease |
ClinicalTrials.gov Identifier: | NCT00196898 History of Changes |
Other Study ID Numbers: |
1.0 / 03.02.05 Grant 01 GI 0201/01 GI 0401 |
First Posted: | September 20, 2005 Key Record Dates |
Last Update Posted: | March 19, 2012 |
Last Verified: | April 2011 |
Keywords provided by German Parkinson Study Group (GPS):
Parkinson´s disease fibrotic valvular heart fibrosis ergot dopamine agonists non-ergot dopamine agonists |
Additional relevant MeSH terms:
Parkinson Disease Heart Diseases Heart Valve Diseases Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Cardiovascular Diseases |
Dopamine Dopamine Agents Dopamine Agonists Cardiotonic Agents Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents |